1. |
Data sources: Canadian Cancer Registry (CCR)
Database (November 2003 file) and Demography Division (population
estimates) of Statistics Canada. |
2. |
World Health Organization, International Classification
of Diseases, 9th Revision (ICD-9) and the World Health Organization,
International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)
and the International Agency for Research on Cancer rules for determining
multiple primaries sites. |
3. |
The CCR is a dynamic database that can be updated
with new records or changes to previous records, therefore, the incidence
counts may vary from one release to the next. From 1976-1991 and
from 2001-2004, age-standardized rate of cancer per 100,000 population,
for all primary sites of cancers (ICD-9 140-208) and for specific sites:
colorectal (ICD-9 153-154), lung (ICD-9 162), female breast (ICD-9 174),
and prostate cancer (ICD-9 185). From 1992-2000, age-standardized
rate of cancer per 100,000 population, for all primary sites of
cancer (using the Surveillance, Epidemiology and End Results Groups for Primary
Site based on ICD-O-2 but adjusted to ICD-O-3) and for specific sites:
colorectal (ICD-O-3 C18.0-C18.9, C19.9, C20.9, C26.0), lung and bronchus
(ICD-O-3 C34.0-C34.9), female breast (ICD-O-3 C50.0-C50.9) and prostate
(ICD-O-3 C61.9). The four categories are excluding morphology types M-9590–M-9989).
Included are all invasive sites and in situ for bladder. |
4. |
Cancer incidence rates are age-standardized
using the direct method and the 1991 Canadian Census population
structure. The use of a standard population results in more meaningful incidence
rate comparisons, because it adjusts for variations in population age distributions
over time and across geographic areas. |
5. |
The confidence intervals for the age-standardized
cancer incidence rates were produced using the Spiegelman method. Reference:
Spiegelman M. "Introduction to Demography", Revised Edition. Cambridge, Massachusetts:
Harvard University Press, 1968, p 113, Formula 4.29. |
6. |
The 95% confidence interval (CI) illustrates
the degree of variability associated with a rate. Wide confidence intervals
indicate high variability, thus, these rates should be interpreted and compared
with due caution. |
7. |
The Merrigan suppression program is used to
suppress low cell counts in cancer data. It suppresses cells with a small
count (less than 6), and also suppresses any cell that could result in
the disclosure of a previously suppressed cell by using the column or row
total. If the variables which define the rows and columns are province and
age group, then the program suppresses low counts first within each province.
If any province contains only one suppressed cell, it suppresses the next
lowest count in that province. It then does the same thing within each age
group. Note: Records where age has not been specified are included in the
total. |
8. |
Nunavut became a territory in April 1999 and
historical data are provided for comparison purposes. Current and historical
cancer data are presented for the current boundaries of the Northwest Territories
and Nunavut. Rates for the Yukon Territory, the Northwest Territories and
Nunavut should be interpreted with caution due to a small underlying count.
|
9. |
Northwest Territories excluding Nunavut. |
10. |
The following standard symbols are used in
Statistics Canada publications: (..) for figures not available for a specific
reference period, (...) for figures not applicable, (f) for forecasts/estimates,
and (x) for figures suppressed to meet the confidentiality requirements of
the Statistics Act. Rates where the case counts are three or fewer have been
suppressed. |
11. |
CANSIM table number 01030104. |